Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Survival in Lung Cancer in the Nordic Countries Through A Half Century

F. Tichanek, A. Försti, O. Hemminki, A. Hemminki, K. Hemminki

. 2023 ; 15 (-) : 503-510. [pub] 20230501

Status not-indexed Language English Country New Zealand

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23009869

OBJECTIVE: Lung cancer is often diagnosed at an advanced stage and survival has been poor, although long-term studies have been rare. We analyzed data on survival in lung cancer from Denmark, Finland, Norway, and Sweden over a 50-year period (1971-2020). METHODS: Relative 1- and 5-year survival data were obtained from the NORDCAN database for 1971-2020. We used generalized additive models to estimate survival trends over time and uncertainty of these estimates. We additionally calculated conditional survival from the 1st to 5th year (5/1-year), estimated annual changes in survival rates, and determined significant breaking points. RESULTS: In 2016-2020, 5-year survival rate for lung cancer was best for Norwegian men (26.6%) and women (33.2%). The sex difference was significant and it was found for each country. Survival improved modestly until the year 2000, after which time survival curves increased steeply and kept the linear shape to the end of follow-up, indicating consistent improvement in survival. Survival curves for 1- and 5/1-year survival were almost superimposable, indicating that deaths in the first year were approximately as many as in the subsequent 4 years, thus marking sustained long-term survival. CONCLUSION: We could document a positive development in lung cancer survival with steep upward trends after the year 2000. Intensions for curative treatment have been increasing and the outcomes have been improving with the help of novel imaging methods. Pathways for facile patient access to treatment have been instituted. Close to 90% of the patients are ever smokers. National anti-smoking acts and alerting people who smoke about early symptoms may be beneficial, as metastatic lung cancer remains difficult to cure.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23009869
003      
CZ-PrNML
005      
20250819101200.0
007      
ta
008      
230707e20230501nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/CLEP.S406606 $2 doi
035    __
$a (PubMed)37153073
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Tichánek, Filip $u Biomedical Center, Faculty of Medicine, Charles University Pilsen, Pilsen, 30605, Czech Republic $u Institute of Pathological Physiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $1 https://orcid.org/0000000341391979 $7 xx0334827
245    10
$a Survival in Lung Cancer in the Nordic Countries Through A Half Century / $c F. Tichanek, A. Försti, O. Hemminki, A. Hemminki, K. Hemminki
520    9_
$a OBJECTIVE: Lung cancer is often diagnosed at an advanced stage and survival has been poor, although long-term studies have been rare. We analyzed data on survival in lung cancer from Denmark, Finland, Norway, and Sweden over a 50-year period (1971-2020). METHODS: Relative 1- and 5-year survival data were obtained from the NORDCAN database for 1971-2020. We used generalized additive models to estimate survival trends over time and uncertainty of these estimates. We additionally calculated conditional survival from the 1st to 5th year (5/1-year), estimated annual changes in survival rates, and determined significant breaking points. RESULTS: In 2016-2020, 5-year survival rate for lung cancer was best for Norwegian men (26.6%) and women (33.2%). The sex difference was significant and it was found for each country. Survival improved modestly until the year 2000, after which time survival curves increased steeply and kept the linear shape to the end of follow-up, indicating consistent improvement in survival. Survival curves for 1- and 5/1-year survival were almost superimposable, indicating that deaths in the first year were approximately as many as in the subsequent 4 years, thus marking sustained long-term survival. CONCLUSION: We could document a positive development in lung cancer survival with steep upward trends after the year 2000. Intensions for curative treatment have been increasing and the outcomes have been improving with the help of novel imaging methods. Pathways for facile patient access to treatment have been instituted. Close to 90% of the patients are ever smokers. National anti-smoking acts and alerting people who smoke about early symptoms may be beneficial, as metastatic lung cancer remains difficult to cure.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Försti, Asta $u Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
700    1_
$a Hemminki, Otto $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland $u Department of Urology, Helsinki University Hospital, Helsinki, Finland
700    1_
$a Hemminki, Akseli $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland $u Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland $1 https://orcid.org/0000000171038530
700    1_
$a Hemminki, Kari $u Biomedical Center, Faculty of Medicine, Charles University Pilsen, Pilsen, 30605, Czech Republic $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany $1 https://orcid.org/0000000227693316 $7 mzk20201092711
773    0_
$w MED00165237 $t Clinical epidemiology $x 1179-1349 $g Roč. 15 (20230501), s. 503-510
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37153073 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230707 $b ABA008
991    __
$a 20250819101143 $b ABA008
999    __
$a ok $b bmc $g 1958540 $s 1196133
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 15 $c - $d 503-510 $e 20230501 $i 1179-1349 $m Clinical epidemiology $n Clin. epidemiol. $x MED00165237
LZP    __
$a Pubmed-20230707
Back

Find record

Citation metrics

Archiving options